


Today's CDMO. **Inspired by tomorrow.**
Sustainability Accounting Standards Board
(SASB)



This index is prepared in alignment with the SASB Biotechnology & Pharmaceuticals Sustainability Accounting Standard, version 2023-12.

Code	Accounting Metric	Category/ Unit of Measure	Response
Safety of Clinical Trial Participants			
HC-BP-210a.1	Discussion of processes, protocols, and data monitoring boards used to ensure participant safety during clinical trials	Discussion & Analysis	As a contract development and manufacturing organization (CDMO), PCI does not conduct clinical trials or have direct interaction with trial participants. Our role is limited to packaging, storage, and distribution of investigational products. Accordingly, processes and data monitoring boards related to participant safety are managed by our clients that sponsor and run the clinical trials, and this metric is not directly applicable to PCI's operations. that provides clinical trial supply services, including packaging, storage and distribution of investigational products
HC-BP-210a.2	Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI), and (2) Official Action Indicated (OAI)	Quantitative/ Number	As a CDMO, this accounting metric is not applicable to our business for the reasons stated above.
HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	Quantitative/ Currency	As a CDMO, this accounting metric is not applicable to our business for the reasons stated above in response to HC-BP-210a.1.



Today's CDMO. **Inspired by tomorrow.**
Sustainability Accounting Standards Board
(SASB)



Access to Medicines


HC-BP-240a.1	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries defined by the Access to Medicine Index	Discussion & Analysis	Not applicable. As a CDMO, PCI has no direct patient-facing activity.
HC-BP-240a.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	Discussion & Analysis	This accounting metric is not applicable to our business. As a CDMO, PCI does not have ownership rights to products.

Affordability & Pricing

HC-BP-240b.2	Percentage change in (1) average list price and (2) average net price across U.S. product portfolio compared to previous year	Quantitative/ Percentage	PCI does not market any of the drug products it produces and is not involved in pricing such products.
HC-BP-240b.3	Percentage change in (1) list price and (2) net price of product with largest increase compared to previous year	Quantitative/ Percentage	PCI does not market any of the drug products it produces and is not involved in pricing such products.

Drug Safety


HC-BP-250a.1	List of products in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for Human Medical Products database	Discussion & Analysis	This accounting metric is not applicable to our business. As a CDMO, PCI does not market any products.
HC-BP-250a.2	Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System	Quantitative/ Number	This accounting metric is not applicable to our business. As a CDMO, PCI does not market any products.



Today's CDMO. **Inspired by tomorrow.**
Sustainability Accounting Standards Board
(SASB)



HC-BP-250a.3	Number of recalls issued; total units recalled	Quantitative/ Number	Zero recalls involving PCI-manufactured batches during the FY25 reporting period. PCI does not hold NDA, BLA, or marketing authorization for any product and cannot independently initiate a recall; however, PCI actively supports client-led recall processes where required.
HC-BP-250a.4	Total amount of product accepted for takeback, reuse, or disposal	Quantitative/ Metric Tonnes	None directly. PCI will support its customers with takebacks, reuse and disposal to meet these obligations, but the responsibility for tracking and monitoring is with the drug product owner.
HC-BP-250a.5	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	Quantitative/ Number	Zero. No FDA enforcement actions were taken in response to violations of current Good Manufacturing Practices during the FY25 reporting period.




Today's CDMO. **Inspired by tomorrow.**
Sustainability Accounting Standards Board
(SASB)



Counterfeit Drugs

HC-BP-260a.1	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	Discussion & Analysis	As a CDMO, PCI supports our customer base in meeting the industry requirements. For finished good commercial products, we implemented a sophisticated product serialization program which applies bar codes and serialized number configurations to track individual units throughout the supply chain. For our clinical supply business, we act as a wholesaler in so much as we request another wholesaler to purchase products on behalf of our client, this is then delivered into our facilities and we “convert” to the required clinical dosage form. We don’t wholesale in the sense that we are “selling” on the products to other wholesalers or primary healthcare establishments (e.g. hospitals, etc.). As a company, we have full electronic traceability of commercial batches received, processed and distributed.
HC-BP-260a.2	Discussion of process for alerting customers and business partners to potential or known risks associated with counterfeit products	Discussion & Analysis	As a CDMO, if a known risk event was highlighted we have policies and procedures in place as well as customer Quality Agreements dictating customer notification, notification timelines and responsible people. Any identified incident will be fully investigated and the results captured within the PCI Quality Management System. Depending on the situation, PCI may be required by law to report such incidents to local authorities as well as regulatory authorities.
HC-BP-260a.3	Number of actions that led to raids, seizure, arrests, or filing of criminal charges related to counterfeit products	Quantitative/ Number	None



Today's CDMO. **Inspired by tomorrow.**
Sustainability Accounting Standards Board
(SASB)




Ethical Marketing

HC-BP-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	Quantitative	This accounting metric is not applicable to our business. As a CDMO, PCI does not market any products directly.
HC-BP-270a.2	Description of code of ethics governing promotion of off-label use of products	Discussion & Analysis	This accounting metric is not applicable to our business. As a CDMO, PCI does not market any products directly. PCI does not market or promote drug products and has no involvement in off-label promotion activities. This metric is not applicable to PCI's business model as a CDMO.

Employee Recruitment, Development, & Retention

HC-BP-330a.1	Discussion of talent recruitment and retention efforts for scientists and research and development staff	Discussion & Analysis	PCI is not an R&D organization; however, our development and manufacturing processes are highly technical and in many cases also uniquely scientific. In FY25, PCI filled 496 roles that are in the science and technology" category, which was 30% of our total filled positions. Of those 496, 196 were external hires, adding this new talent to the organization.
HC-BP-330a.2	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) mid-level managers, (c) professionals, and (d) all others	Quantitative/ Percentage (%)	Not disclosed. For more information on employee engagement and retention, please see our FY25 Sustainability Report, which is publicly available on our corporate website: https://pci.com/cdmo-sustainability



Today's CDMO. **Inspired by tomorrow.**
Sustainability Accounting Standards Board
(SASB)



Supply Chain Management

HC-BP-430a.1	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit programme or equivalent third- party audit programmes for integrity of supply chain and ingredients	Quantitative/ Percentage (%)	PCI uses approved suppliers who are regularly audited by credible parties, such as the Pharmaceutical Supply Chain Initiative and the Rx-360 International Pharmaceutical Supply Chain Consortium. If issues are identified during an audit, the supplier is required to prepare a Corrective Action Plan and resolve all issues within an agreed-upon timeframe. As of June 30, 2025, the average score of 237 organizations in our EcoVadis network is 62.8/100.
--------------	---	---------------------------------	--

Business Ethics

HC-BP-510a.1	Total amount of monetary losses as a result of legal proceedings associated with corruption, bribery, or anti-competitive behavior	Quantitative	None
HC-BP-510a.2	Description of code of ethics governing interactions with health care professionals	Discussion & Analysis	This accounting metric is not applicable to our business. PCI operates as a B2B CDMO and does not engage with healthcare professionals in a sales or promotional capacity. Where PCI interacts with healthcare professionals through clinical supply services, these interactions are governed by client Quality Agreements. A standalone code of ethics for HCP interactions is not applicable to PCI's business model.

Activity Metrics

HC-BP-000.A	Number of patients treated	Quantitative/ Number	As a CDMO, PCI does not treat patients.
HC-BP-000.B	Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)	Quantitative/ Number	There are approximately 2,000 molecules within PCI's portfolio. Approximately 1,158 (58%) of those molecules are in the Research and Development stage (phase 1-3).

